A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Sickle cell anaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 08 Oct 2018 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2018 Planned primary completion date changed from 19 Mar 2020 to 1 Apr 2019.